中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
22期
2202-2204
,共3页
门冬氨酸钾镁%腺苷蛋氨酸%胆汁淤积性病毒性肝炎%肝功能
門鼕氨痠鉀鎂%腺苷蛋氨痠%膽汁淤積性病毒性肝炎%肝功能
문동안산갑미%선감단안산%담즙어적성병독성간염%간공능
potassium-magnesium cholestatic%ademetionine%cholera viral hepatitis%liver function
目的 探讨门冬氨酸钾镁和腺苷蛋氨酸在胆汁淤积性病毒性肝炎患者中的临床疗效. 方法 80例胆汁淤积性病毒性肝炎患者分为对照组和试验组,各40例. 试验组静脉滴注门冬氨酸钾镁30 mL,对照组静脉滴注腺苷蛋氨酸1000 mg,连续治疗4周,比较2组的临床疗效,观察2组患者治疗前后的临床症状和肝功能指标改善情况. 结果 试验组有效率为95.0%,显著高于对照组的85.0%( P<0.05 ). 治疗后,2组谷丙转氨酶、谷草转氨酶、总胆红素、直接胆红素、碱性磷酸酶和γ-谷氨酰转肽酶显著低于治疗前,且试验组显著低于对照组(P<0.05). 试验组临床症状改善率为85.0%,显著高于对照组的57.5%(P<0.05). 试验组不良反应发生率为 7.5%,显著低于对照组的 17.5%( P <0.05). 结论 门冬氨酸钾镁对胆汁淤积性病毒性肝炎的临床疗效显著,且不良反应发生率低.
目的 探討門鼕氨痠鉀鎂和腺苷蛋氨痠在膽汁淤積性病毒性肝炎患者中的臨床療效. 方法 80例膽汁淤積性病毒性肝炎患者分為對照組和試驗組,各40例. 試驗組靜脈滴註門鼕氨痠鉀鎂30 mL,對照組靜脈滴註腺苷蛋氨痠1000 mg,連續治療4週,比較2組的臨床療效,觀察2組患者治療前後的臨床癥狀和肝功能指標改善情況. 結果 試驗組有效率為95.0%,顯著高于對照組的85.0%( P<0.05 ). 治療後,2組穀丙轉氨酶、穀草轉氨酶、總膽紅素、直接膽紅素、堿性燐痠酶和γ-穀氨酰轉肽酶顯著低于治療前,且試驗組顯著低于對照組(P<0.05). 試驗組臨床癥狀改善率為85.0%,顯著高于對照組的57.5%(P<0.05). 試驗組不良反應髮生率為 7.5%,顯著低于對照組的 17.5%( P <0.05). 結論 門鼕氨痠鉀鎂對膽汁淤積性病毒性肝炎的臨床療效顯著,且不良反應髮生率低.
목적 탐토문동안산갑미화선감단안산재담즙어적성병독성간염환자중적림상료효. 방법 80례담즙어적성병독성간염환자분위대조조화시험조,각40례. 시험조정맥적주문동안산갑미30 mL,대조조정맥적주선감단안산1000 mg,련속치료4주,비교2조적림상료효,관찰2조환자치료전후적림상증상화간공능지표개선정황. 결과 시험조유효솔위95.0%,현저고우대조조적85.0%( P<0.05 ). 치료후,2조곡병전안매、곡초전안매、총담홍소、직접담홍소、감성린산매화γ-곡안선전태매현저저우치료전,차시험조현저저우대조조(P<0.05). 시험조림상증상개선솔위85.0%,현저고우대조조적57.5%(P<0.05). 시험조불량반응발생솔위 7.5%,현저저우대조조적 17.5%( P <0.05). 결론 문동안산갑미대담즙어적성병독성간염적림상료효현저,차불량반응발생솔저.
Objective To investigate the clinical effect of potassium-magnesium aspartate and ademetionine in patients with cholestatic viral hepatitis.Methods A total of 80 cases with cholestatic viral hepatitis were divided into experiment group and control group, each 40 cases. Experiment group was given intravenous potassium magnesium aspartate 30 mL, and control group was given intravenous ademetionine 1000 mg.Cli-nical efficacy and clinical symptoms and liver function before and after treatment were observed. Results The effective rate was 95.0% in experiment group, significantly higher than 85.0% in control group (P<0.05).After treatment, the alanine aminotransferase(ALT), aspar-tate aminotransferase ( AST ) , total bilirubin ( Tbil ) , direct bilirubin ( Dbil ) , alkaline phosphatase ( ALP ) and γ-glutamyl endopeptidase ( GCT ) were significantly lower than those before treatment , and experiment group lower than control group (P<0.05).The improvement rate of clinical symptoms in experiment group was 85.0%, significantly higher than that in control group, which was 57.5% ( P <0.05) .The incidence of adverse reactions was 7.5%in experiment group, significant-ly lower than 17.5%in control group (P<0.05).Conclusion Clinical efficacy of potassium-magnesium aspartate on cholestatic viral hepatitis patients was significant, with low incidence of adverse reactions.
